ArticleThe Lancet regional health. Southeast Asia2026
Incidence and mortality of invasive fungal infections among patients admitted in intensive care units in India: findings from a multicentric registry-based study (2023-25).
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive fungal infections (IFIs) are challenging to treat in critical care, particularly among patients treated in Intensive care units (ICUs). The existing evidence on IFIs from India remains fragmented. This study characterises IFI incidence, risk factors, resistance pattern, treatment and outcome among patients admitted to ICUs. Methods: This multicentre observational study leveraged registry data on IFIs among patients admitted to 63 ICUs in eight Advanced Mycology Diagnostic and Research centres in India between January 2023 and November 2025. Patients with proven and probable IFI according to European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) 2020 and the modified Aspergillus intensive care unit (AspICU) 2020 criteria were included. IFI incidence to hospital admission, all-cause in-hospital mortality, pathogen distribution and antifungal susceptibility were recorded. Mortality-associated factors were estimated using multivariable logistic regression and Cox proportional hazards analysis. Findings: Among 178,417 ICU admissions, 2500 IFI patients were identified with an incidence of 14/1000 admissions (95% CI 13.5-14.6) and all-cause mortality of 53.6% (95% CI 51.7-55.6%). Invasive candidiasis was the most frequently reported (57.1%), followed by invasive aspergillosis (37%), mucormycosis (3.4%), trichosporonosis (1.8%), pneumocystis pneumonia (1.1%), and cryptococcosis (1.2%). Median age of the patients was 45 years (IQR: 26-60), with 61.9% males and 38.1% females. Among candidiasis, Interpretation: The study findings highlight a high IFI burden and mortality among patients admitted in ICUs of India, with mortality exceeding 50%, underscoring the need for continuous surveillance, rapid diagnostics, infection control and antifungal stewardship. Funding: This study was funded by the Indian Council of Medical Research (ICMR), Delhi (Grant ID: 157401).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.